
























Poly(ADP-ribosyl)ation (PARylation) is a reversible post-translational modification of 
cellular proteins. The dynamic process of PARylation is balanced through synthesis of 
poly(ADP-ribose) (PAR) on substrates by PAR polymerases (PARP) and degradation of 
the polymer by PAR glycohydrolase. Here we report that overexpression of RNF146 and 
its PAR-binding WWE domain led to an increase in endogenous PAR level in multiple 
cell lines. Moreover, we showed that the increase in PARylation level was likely due to 
an increase in the steady-state level of certain PARylated proteins such as PARP5a 
(Tankyrase 1) and PARP5b (Tankyrase 2). At a single cell level, we observed the 
formation of PAR/Tankyrase-rich puncta in HeLa cells by overexpressing RNF146 
WWE domain. We also demonstrated the PAR induction by RNF146 WWE domain was 
tightly linked to its affinity for PAR. Mutations in RNF146 WWE domain reducing PAR 
binding (Q155A, Y143A and R163A) also impaired PAR/TNKS induction level upon 
overexpression in cells. We illustrated that such a characteristic property of RNF146 
WWE domain was not a common feature shared by every member in the mammalian 
WWE domain family. Lastly, we proposed and explored the idea of engineering RNF146 
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ADP-ribosylation refers to the attachment of ADP-ribose units onto target 
proteins. It was first identified as a nucleic acid product resulting from addition of 
nicotinamide mononucleotide in chicken liver nuclear extracts in the absence of the other 
nucleotide triphosphates (Chambon and Mandel, 1963). Further analysis discovered the 
chemical structures of this product as a polymer of ADP-ribose (Chambon et al., 1966). 
The post-translational modification can exist in two forms: poly(ADP-ribosy)lation 
(PARylation) and mono(ADP-ribosy)lation (MARylation). As their names indicate, 
MARylation is a process attaching single ADP-ribose (ADPr) units onto proteins, 
whereas PARylation allows attachment of additional ADPr units to form a polymer chain 
on a target protein. The chain can be elongating either in a linear or branched fashion up 
to hundreds of units in length. Both in the linear portions and at branched points of PAR 
chains, ADPr units are covalently connected by 𝛂(1-2) ribose–ribose bonds (Miwa et al., 
1981). However, the exact significance of differences in PAR chain structures is still 
unclear. After the discovery of ADP-ribosylation, enzymes that catalyze the reactions 
were also identified over the years and commonly known as poly(ADP-ribose) 
polymerase (PARP). To date, 17 PARPs have been discovered in mammalian cells (Vyas 
et al., 2014). In general, PARPs can transfer ADPr from NAD+ to the specific target 
residues of a protein. Recent studies have indicated that 4 out of 17 mammalian PARPs, 
namely, PARP1, PARP2, PARP 5a, and PARP5b (also known as Tankyrase 1 and 2, or 
TNKS 1 & 2), are capable of carrying out PARylation in vitro. On the other hand, both 
major isoforms of PARP13 as well as PARP9 have been characterized as catalytically 
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inactive for ADP-ribosylation, whereas the other PARPs are believed to catalyze 
MARylation in cells (Vyas et al., 2014). Given the fact that some members of the PARP 
family can only carry out the MARylation process, a new nomenclature, “ADP-
ribosyltransferase, diphtheria toxin-like” (ARTD), has been proposed in the field 
(Hottiger, 2015). Meanwhile, there are cellular enzymes that continuously remove ADP-
ribosylation from modified proteins. Both poly(ADP-ribose) glycohydrase (PARG) and 
ADP-ribosylhydrolase 3 (ARH3) can facilitate the cleavage of ribose–ribose bonds 
within PAR polymers. Active isoforms of PARG can be found in both the cytoplasm and 
the nucleus while active ARH3 is mainly located in the cytoplasm, mitochondria and the 
nucleus (Slade et al., 2011; Niere et al., 2012; Mashimo, 2014). Other enzymes, such as 
ADP-ribosylarginine hydrolase 1 (ARH1) and MacroD2, can reverse MARylation 
processes. Although little is known about the biological role of mono-ADP-
ribosylhydrolases, ARH1 specifically removes mono-ADP-ribose from the arginine 
residues of target proteins, whereas MacroD2 extends its activity to acidic residues, such 
as glutamate (Mashimo, 2014; Rosenthal et al., 2013).  
 The rapid addition and removal of ADPr units onto a variety of substrates allows 
cells to quickly adapt to different biological environments. Indeed, the significance of 
PARylation in regulating cellular processes that are critical for cell survival has been 
demonstrated. PARP1, the founding member of the PARP family, has been largely 
characterized for its involvement in DNA damage responses and chromatin remodeling. 
PARP1 can directly sense single-strand breaks upon DNA damage. Binding to DNA 
through its zinc finger domains, PARP1 relocates itself to the lesion sites and PARylates 
selected proteins involved in DNA repair (Langelier and Pascal, 2013). Additionally, 
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PARP1 can PARylate itself. Auto-PARylation is believed to prevent excessive binding 
and activity of PARP1 by charge–charge repulsion between the DNA phosphate 
backbone and PAR polymers (Zahradka and Ebisuzaki, 1982). At the same time, the 
modification is reversed by PARG to block hyper-PARylation. The dynamic process of 
PARylation with PARP1 and PARG leads to several consequences. First, branched PAR 
polymers at lesion sites serve as a scaffold to recruit downstream molecules, such as 
XRCC, through non-covalent interactions to initiate the DNA repair processes. Second, 
the branched PAR polymers result in the further amplification of stress signals to the 
close proximity of the lesion sites (Caldecott, 2003). Moreover, PARylation by PARP1 
also facilitates chromatin remodeling during DNA damage response. Although the exact 
functions involved are still debatable, the remodeling event is believed to open up 
chromatin structures for repair and regulate the expression of certain transcription factors 
(Messner and Hottiger, 2011). Recent studies have also indicated the presence of 
PARylation in DNA double-strand break repair. Data suggest that multiple protein 
complexes, including BRCA1-BARD1 and RAP80, are recruited to the lesion sites by 
PARP1 activity at different time points during the repair processes (Li and Yu, 2013; Hu 
et al., 2014). 
 The discovery of PARP1 biological functions in DNA repair has led to the 
development of new therapeutics. PARP inhibitors, standalone or in combination with 
chemotherapy, have become a novel strategy to treat breast and ovarian cancers 
(Plummer, 2015). By inhibiting PARP1 activity and causing apoptosis in BRCA-deficient 
tumor cells, PARP inhibitors block single-strand break repair (Ashworth, 2008). On 
December 19th, 2014, a PARP1 inhibitor, Olaparib, was approved by the Food and Drug 
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Administration for clinical application in treating ovarian cancer patients (Olaparib 
Approved for Advanced Ovarian Cancer, 2015). Moreover, another PARP inhibitor 
rucaparib was granted breakthrough therapy designation by the FDA for treating ovarian 
cancer patients with BRCA1/2 mutations (Kristeleit et al., 2015). Several other PARP 
inhibitors, including veliparib, niraparib, and talazoparib, are currently going through late 
phase clinical trials (Brown et al., 2016). 
 Beyond DNA repair, PARylation is also involved in other cellular regulations. 
For instance, poly(ADP-ribose)-dependent ubiquitination (PARdU), a novel pathway for 
protein degradation, has recently been discovered. Proteins modified by Tankyrase 1 and 
2 (TNKS 1 & 2, also known as PARP 5a & 5b) are recognized by the E3 ubiquitin ligase 
RNF146 through its PAR-binding WWE domain, leading to proteasomal degradation 
(Zhang et al, 2011) (See also next two sections). Demonstrating a new level of 
complexity for cellular signaling pathways, PARdU serves as a cross-talk between 
PARylation and ubiquitination. Additionally, the role of PARylation in stress-granule 
formation has also been demonstrated. Five PARPs, namely, PARP 5a, 12, 13, 14, and 
15, and two PARG isoforms haven been found to localize to stress granules (Leung et al., 
2011). Overexpression of these PARPs results in stress granule formation without 
additional treatment. On the other hand, overexpression of PARGs prevents the assembly 
of stress granules. Furthermore, when PARG knockdown is performed, a prolonged 
presence of stress granules is observed after cellular stresses are removed. All these data 
suggest that PAR polymers provide a structural basis for the assembly of stress granules, 
and PARPs might be the driving force during this process	(Leung et al., 2011, 2012). In 
addition, PARylation has been identified for its involvement in a variety of other cellular 
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processes, such as mitotic spindle assembly and telomere maintenance by PARP 5a 
(Chang et al., 2005; Ramamootthy and Smith, 2015). 
 
Ubiquitination and E3 ligases 
 Ubiquitination is a post-translational modification that regulates protein stability, 
interaction, and localization in cells (Ye and Rape, 2009). The cellular ubiquitin system 
consists of several components: ubiquitin itself and E1, E2, and E3 enzymes. E1 
enzymes, also known as ubiquitin-activation enzymes, uses ATP to activate free 
ubiquitin, which results in a conjugation formed by a thioester linkage between the 
active-site cysteine residue of E1 enzymes and the C-terminus of ubiquitin. Then, 
ubiquitin is transferred from the E1 to E2 and eventually passed along to the E3 
(ubiquitin E3 ligase). Studies reveal that only a few E1 enzymes but over 600 E3s are 
present in mammalian cells (Welchman et al., 2005). As a result, the specificity of 
ubiquitination is mainly achieved through E3s. Ubiquitin can be linked through one of 
seven lysine residues or the N-terminus of the protein, which results in polyubiquitin with 
different linkages. The types of linkages within polyubiquitin chains specify the cellular 
functions of the modification. For instance, polyubiquitin chains with Lys48 linkage 
facilitates protein degradation through the proteasome; Chains with Lys63 linkage are 
associated with DNA repair, intracellular trafficking, protein–protein interactions, and 
ribosomal biogenesis (Li and Ye, 2008). E3 ligases can be categorized into two types on 
the basis of their ubiquitination activities. They either serve as catalytic enzymes, or they 
function as a platform to bring E2 and substrates in close proximity. Homologous to E6-
AP Carboxy Terminus (HECT) E3 ligases use the former mechanism, whereas the latter 
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one is a feature shared by Really Interesting New Gene (RING) E3 ligases (Fang and 
Weissman, 2004). HECT-type E3s transfer ubiquitin from E2 to themselves and then 
continue the transfer to substrates.  
 
RNF146 
The RING-type ubiquitin E3 ligase RNF146 (also known as Iduna) was first 
discovered for regulating axin degradation in Wnt/β-catenin signaling pathway through a 
cross-talk between ubiquitination and PARylation (Zhang et al., 2011; Callow et al., 
2011). PARylated axin is recognized by RNF146 and targeted for proteasomal 
degradation. Since β-catenin, a cell survival factor, is regulated by an axin-containing 
degradation complex, overexpression of RNF146 causes elevated levels of β-catenin and 
thus leads to enhanced tumor proliferation (Guo et al., 2013). Along with PARylated 
axin, auto-PARylated TNKS 1 & 2 have also been reported as substrates of RNF146 E3 
ligase activity (Callow et al., 2011; Zhang et al., 2011). On the other hand, RNF146 has 
also been shown to have neuroprotective functions. Activation of NMDA receptors in 
glutamatergic neurons leads to upregulation of RNF146 expression. The ubiquitin E3 
ligase is believed to counteract PARP1-promoted apoptosis after NMDA-induced 
excitotoxicity in a PAR-dependent manner (Andrabi et al., 2011). A later study also 
suggested that RNF146 can bind to PARylated DNA repair proteins, such as XRCC1, 
histones, Ku70, DNA ligase III, and PARP1 itself, to assist DNA damage repair in cells 
(Kang et al., 2011).  
 Understanding toward the complicated physiological roles of RNF146, as being 
either oncogenic or neural protective, cannot be achieved without further insights into the 
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molecular basis behind its ubiquitin E3 ligase activity. Despite the many studies reporting 
on the cellular functions of RNF146, only a few have examined the molecular 
mechanisms behind its effects. RNF146 consists of several domains/motifs. The RING 
domain sits near the amino-terminus of the RNF146 sequence, which is responsible for 
its ubiquitin E3 ligase activity, followed by a short linker region and then a domain called 
the WWE domain (see more in next section). The linker region provides the flexibility 
for two domains to carry out their functions properly. The WWE domain has been 
identified for its binding affinity for iso-ADP ribose (iso-ADPr), an internal unit of the 
PAR polymer (Figure 1, adapted from Leung, 2014). The long and unstructured region at 
the carboxyl-terminus of RNF146 presumably contains several motifs for interactions 
with TNKS (DaRosa et al., 2015). Using GST-tagged wild-type RNF146 was able to pull 
down the TNKS five ankyrin repeat clusters (TNKS 5ARC) fragment in vitro while 
mutants with a truncated or mutated C-terminus failed to do so (DaRosa et al., 2015). 
Nonetheless, the exact mechanism behind the interaction between TNKS and RNF146 is 
still unclear. As a RING-type E3 ligase, RNF146 can directly transfer ubiquitin from E2 
ligases to substrates. In addition, ubiquitination by RNF146 is robustly increased from the 
basal level when it binds to PARylated substrates through its WWE domain. Tracing the 
rate of ubiquitin transfer from the E2-ubiquitin complex to a free lysine in vitro can 
qualitatively measure and compare the E3 ligase activity of RNF146 with or without 
binding to PAR. Addition of purified iso-ADPr or PAR polymers, but not ADPr, to full-
length RNF146 could completely release ubiquitin from the UbcH5c(E2)-ubiquitin 
complex to a free lysine within 4 minutes. In contrary, without addition of iso-ADPr or 
PAR, the majority of ubiquitin remain bound to the E2-ubiquitin complex within the 4-
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minute time period (DaRosa et al., 2015). Moreover, measuring the rate of ubiquitn 
transfer using the RING–WWE fragment of RNF146 gives a comparable result, 
indicating that the RING–WWE region is the basic functioning unit of RNF146 for its E3 
ligase activity.  
The partial crystal structure indicates the binding of iso-ADPr between the RING 
and WWE domains through its contact with several residues in both domains. On the 
other hand, phosphate groups on both sides of iso-ADPr are exposed to the outside, 
which explains how RNF146 can interact with PAR polymers (Wang et al., 2011). 
Additionally, the binding to iso-ADPr triggers a conformational change in the RING 
domain that favors E2 interaction. The stabilization of the E2–E3 interface translates into 
elevated ubiquitination activity by RNF146. An additional mutagenesis study revealed 
the details behind such a phenomenon. Lys 61 couples ligand binding to the activation of 
the RING domain by facilitating the formation of a central helix that orients the two Zn2+ 
loops for E2 binding. On the other hand, Gly 62 and Trp 65 help stabilize the inactive 
form by disrupting helix formation. The substitution of Lys 61 to Ala or Asp abolishes 
the activation of E3 ligase activity while the mutant can still bind to iso-ADPr. On the 
contrary, mutations in Gly 62 and Trp 65 increase the basal level of E3 activity (DaRosa 
et al., 2015). A second study confirms that mutations in similar regions of RNF146 affect 
its E3 ligase activity (Kang et al., 2011). In summary, the current experimental evidence 
supports a model in which binding of PAR chains derived from PARylated proteins 
activates RNF146 ubiquitin E3 ligase activity by triggering a conformational change in 








Figure 1 | Structure of poly(ADP-ribose) polymers and its interacting domains. The 
minimum structural units within PAR that are recognized by each interacting 
domains are highlighted. The WWE domain is capable of binding to iso-ADP-ribose 
motifs; Marco domains recognize distal ADP-ribose motifs while PBZ domains interact 




WWE domains were first identified by a multiple sequence alignment using PSI-
BLAST (Aravind, 2001). The domain was named after the three conserved residues 
within the sequences, Trp(W), Trp (W), and Glu (E). A secondary-structure prediction as 
well as NMR structures indicated the presence of multiple beta-strands and a central 
alpha-helix, as common features shared by members of the WWE family (He et al., 
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2012). The best-described member is the RNF146 WWE domain. The crystal structure, 
along with the mutagenesis study, has demonstrated the molecular basis for binding iso-
ADPr by the RNF146 domain. The RNF146 WWE domain forms a half beta barrel 
structure that consists of six beta sheets and a central alpha-helix between the second and 
third sheets. The surface of the binding pocket within the half beta barrel is positively 
charged, which allows the accommodation of iso-ADPr. Within the pocket, Tyr144 and 
Arg163 make contact with the phosphate group on one side of iso-ADPr, whereas 
Arg110, Trp114, and Lys175 interact with the other phosphate group and ribose (Figure 
2a, adapted from Wang et al., 2012). The unique interaction between residues and two 
phosphate groups on both sides provided the rationale for the specificity of the RNF146 
WWE domain toward iso-ADPr but not ADPr. On the other hand, the fact that both ends 
of iso-ADPr are exposed when it is bound by the WWE domain further provides evidence 
of how RNF146 can bind to PAR polymers. Moreover, the hydrogen bonding formed by 
Gln153 with the adenine ring, as well as the stacking effect by the Tyr107 phenol group, 
also assists the positioning of the adenine ring and the ribose group in the binding pocket 
of the RNF146 WWE domain. Data generated by isothermal titration calorimetry (ITC) 
have shown that changing Tyr107, Tyr144A, or Arg163 to Ala will abolish the iso-ADPr 





Figure 2 | Recognition of iso-ADPr motif by RNF146 WWE domain. a) Key residues 
in RNF146 WWE domain that are involved in binding iso-ADPr. Hydrogen bonds are 
represented by dashed lines. Water molecules are represented by red spheres. b) 
Mutagenesis analysis of key residues in RNF146 WWE domain for iso-ADPr binding. 
Dissociation constants shown in the table were measured by isothermal titration 
calorimetry (ITC) analysis (adapted from Wang et al., 2012).  
 
Although the RNF146 WWE domain has been largely studied, little is known 
about other WWE domains, especially those that are found in proteins within mammalian 
cells. Recognition of iso-ADPr is likely a common feature of WWE domains, with a few 
exceptions. In particular, a functional resemblance in PAR interaction among E3 ligase 
WWE domains exists (Wang et al., 2011). By contrast, the true nature of PARP WWE 
domains, and most importantly, how these domains contribute to PARP activities, remain 
unclear. To date, 12 mammalian proteins have been identified to carry WWE domain(s) 
(Figure 3, adapted from Kalisch et al., 2012). Among them, RNF146, HUWE1, TRIP12, 
and Deltex 1, 2, and 4 are ubiquitin E3 ligases, whereas tiPARP (PARP7) and PARP 11, 
12, 13, and 14 are PAR polymerases. DDHD2 is the only phospholipase found with a 
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WWE domain within the structure. Deltex 1, 2, and 4, as well as PARP 12, contain two 
WWE domains, and the rest contain only one (Kalisch et al., 2012).   
 
 
Figure 3 | Schematic diagram for human WWE-domain containing proteins. WWE 
domains in each protein are highlighted in yellow (adapted from Kalisch et al., 2012). 
 
PAR induction – a novel phenomenon of RNF146 and its WWE domain 
As a master mediator between ubiquitination and PARylation pathways, RNF146 
has caught our attention. Intriguingly, our curiosity toward RNF146 and other WWE 
domain-containing proteins has led us to discover a new property of RNF146 from an 
experimental control. Previous work, done by my lab colleague Dr. Yoshinari Ando 
(unpublished data), suggested that overexpression of mouse RNF146 or its WWE domain 
in 293F cells, but not PARP13.1, 13.2, or GFP alone, were able to increase signals for 
endogenous PAR in cell lysates detected by western blot (Figure 4). Given that all 
samples went through the same preparation, the elevated cellular PAR level was unlikely 
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due to the transfection procedure. Additionally, even though GFP was expressed at a 
higher level, it failed to induce the cellular level of PAR. Thus, it is also unlikely that the 
increased PAR signal was due to the amount of protein overexpression. Although the 
WWE domain was a common feature shared by PARP13.1, PARP13.2, and mouse 
RNF146 (mRNF146), only overexpression of RNF146 increased cellular PAR levels 
detected on western blot, suggesting that this property is not shared by overexpression of 
any WWE domain-containing protein. Here, in this thesis, we further characterize 
RNF146 and the role of its WWE domain in affecting PAR levels in the cell, as well as 
explore the possibility of engineering the RNF146 WWE domain into a molecular tool 
for modulating cellular PARylation events. 
 
(Next Page) Figure 4 | Overexpression of mouse RNF146 (mRNF146) and its WWE 
domain result in elevated levels of cellular PAR. Western blots of total cell lysates 
from 293F cells expressing GFP, GFP-tagged PARP13.1, PARP13.2, mRNF146 and 
mRNF146 WWE domain using antibodies against PAR (left) and GFP (right). (Data 















HEK293F cell transfection and harvesting 
Twenty milliliters of HEK293F cells were seeded at 5 x 105 cells/mL density in a 
125 mL flask the day before transfection. The cells were incubated at 37 °C with 8% CO2 
content and then shaken constantly at a speed of 135 rpm for 24 h.   
  Plasmid DNA was added to a 230 µL solution of Opti-MEM (31985070, Gibco) 
as mixture A. Then, 20 µL of 293fectin (12347-019, Invitrogen) was mixed with 230 µL 
of Opti-MEM and incubated at room temperature for 5 min as mixture B. Mixtures A and 
B were combined and incubated for 20 min at room temperature. The solution was then 
added to the cell culture before the transfected cells were incubated for another 24 h at 
37 °C with 8% CO2 content and shaken constantly at a speed of 135 rpm.  
 The transfected HEK293F cells were collected after being spun down at 400 xg 
for 5 min. The cell pellets were washed with 10 mL of cold PBS (10010-049, Gibco). 
The cell pellets were then lysed on ice for 10 min with the use of mRIPA buffer (50 mM 
Tris-HCl pH7.4, 150 mM NaCl, 0.1% sodium deoxycholate, 1% NP-40, 1 mM EDTA pH 
8.0, 1x SigmaFast Protease Inhibitor) with 1 µM ADP-HPD (118415, EMD Millipore). 
The supernatant was collected after a spin-down solution at 14,000 rpm for 15 min at 
4 °C. Then, 0.25 µL of 1 mg/mL cytochalasin (sc-201442, Santa Cruz) was added to the 
cell lysates and incubated on ice for 10 min. The lysates were diluted with 2x protein 
loading buffer (62.5 mM Tis-HCL pH6.8, 25% glycerol, 2%SDS, and 0.1% Orange G 




HEK293T cell transfection and harvesting 
 Two milliliters of HEK293T cells were seeded at 5 x 105 cells/mL density in a 
six-well plate (82050-842, Cellstar) the day before transfection. The cells were incubated 
in a cell chamber at 37 °C and 5% CO2 content for 24 h. 
 Before transfection, the amount of cell medium was reduced to 1 mL per well. 
Plasmid DNA was added to 150 µL solution of Opti-MEM as mixture A. Six microliters 
of LipofectamineTM 2000 (1168027, invitrogen) was mixed with 230 µL of Opti-MEM 
and incubated at room temperature for 5 min as mixture B. Mixtures A and B were then 
combined and incubated for 10 min at room temperature. The solution was added to the 
cell medium in each well. The transfected cells were incubated for another 24 h at 37 °C 
with 5% CO2 content.  
 The six-well plate was placed on ice before harvesting. The transfected cells were 
collected with 1.5 mL of cold PBS and spun down at 400 xg for 5 min after removal of 
the medium. The cell pellets were lysed with 150 µL 1x protein loading (31.25 mM Tis-
HCL pH 6.8, 12.5% glycerol, 1% SDS, and 0.05% Orange G dye). The cell lysates were 
transferred to QIAshedder tubes (79656, Qiagen) and spun down at 14,000 rpm for 2 min 
to remove high-molecule-weight genomic DNA and other viscous cell components. 
 
HeLa cell/DLD1 cell transfection and harvesting 
  The cell seeding and transfection processes were the same, as indicated in the 
HEK293T cell transfection and harvesting section, except for a change of the cell 
medium used for the HeLa cells at a 6 hr time point after transfection.  
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 The six-well plate was placed on ice before harvesting. The transfected cells were 
washed twice with 1 mL of cold PBS after removal of the medium. Then, 150 µL 1x 
protein loading buffer was used to lyse the cells in each well. The cell lysates were 
transferred to QIAshedder tubes and spun down at 14,000 rpm for 2 min to remove high-
molecule-weight genomic DNA and other viscous cell components. 
 
Western Blot 
The cell lysates were heated at 95 °C for 5 min before they were loaded on a 
home-made 10% SDS-PAGE gel (30% polyacrylamide, 25% 1.5 M Tris-HCL pH 8.8, 
10% ammonium persulfate, 10% SDS 1% TEMED). The samples were run at 150 V until 
the loading dye passed the bottom of the gel; they were then transferred onto a 
nitrocellulose membrane (GE10600007, Sigma-Aldrich) with either overnight wet 
transfer (at 12 V for 16 h) or semi-dry transfer (at 15 V for 50 min) method. The 
membrane was blocked with 4% skin milk (A614-1000, Quality Biological) in TBS (20 
mM Tris-HCl pH 7.4, 150 mM NaCl) for 1 h at room temperature. The primary antibody 
was diluted in TBST (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Tween20, 0.01% 
thimerosa) and incubated with membrane at 4 °C overnight. After three 10-minute 
washes with TBST, the membrane was incubated with a secondary antibody (diluted in 
15 mL of 4% skin milk in TBST) for 40 min. The membrane was scanned on a LI-COR 
Odyssey Imager after three additional 10-minute washes with TBST. The following 
antibodies were used for Western blot: rabbit polyclonal anti-PAR antibody (4336-BPC, 
Trivegen, USA), mouse anti-GFP (11814460001, Roche, USA), rabbit anti-TNKS 1&2 
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(H-350) (sc-8337, Santa Cruz, USA), anti-axin (AF3287, R&D System, USA), and 




For the PCR reaction using Q5 polymerase (M0491L, NEB), the reaction mixture was set 
up as follows: 
5X Q5 Reaction buffer – 5 µl 
10 mM dNTPs – 0.5 µl 
10 µM Forward Primer – 1.25 µl 
10 µM Reverse Primer – 1.25 µl 
Template Plasmic DNA – 4 µl 
Q5 polymerase – 0.25 µl 
5X Q5 Enhancer – 5 µl 
ddH2O 
________________________________________ 







The Q5 PCR reaction steps were as follows: 
1. 98 °C, 1 min 
2. 98 °C, 20 sec 
3. Lowest Tm + 3 °C, 30 sec 
4. 72 °C, 30 sec/kb 
5. 72 °C, 2 min 
6. 4 °C, ∞ 
*Repeat steps 2–4 30 times 
For the PCR reaction using Taq polymerase (M0267L, NEB), the reaction mixture was 
set up as follows: 
10x Thermo buffer – 2.5 µL 
10 µM FP.for primer – 0.5 µL 
10 µM FP.rev primer – 0.5 µL 
dNTP mix – 0.5 µL 
colony DNA as template 
ddH2O –18.875 µL 
NEB Taq polymerase – 0.125 µL 
________________________________________ 
Total: 25 µL 
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The Q5 PCR reaction steps were as follows:  
1. 95 °C, 3 min 
2. 95 °C, 20 sec 
3. Tm: 5 °C, 30 sec 
4. 68 °C, 30 sec/kb 
5. 68 °C, 5 min 
6. 4 °C, ∞ 
*Repeat steps 2–4 30x 
Restriction enzyme digestion 
The reactions for double-enzyme digestion were carried out with FastDigest 
restriction enzymes (XhoI-FD0694, BamHI-FD0054, HindIII-FD0504, BbsI-FD1014, 
EcoRI-FD0274, PstI-FD0614, Thermo Fisher) and FastAP alkaline phosphatase 
(EF0651, Thermo Fisher). 
The reaction mixture for processing the vector plasmid was set up as follows: 
Plasmid DNA – 3 µg 
10 x FastDigest Buffer – 2 µL 
FastDigest enzyme I – 1 µL 
FastDigest enzyme II – 1 µL 
FastAP alkaline phosphatase – 1µL 
ddH2O 
________________________________________ 
Total: 20 µL 
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The reaction was mixed thoroughly with constant shaking and then incubated at 
37 °C for 30 min. The reaction products were analyzed on 1% agarose gel. The DNA 
fragments with correct size were purified with a Qiagen Gel purification kit (28704, 
Qiagen). The manufacturer’s protocol was followed for the PCR purification. 
The reaction mixture for processing the DNA insert was set up as follows: 
DNA insert – 10 µL 
10 x FastDigest Buffer – 2 µL 
FastDigest enzyme I – 1 µL 
FastDigest enzyme II – 1 µL 
ddH2O 
________________________________________ 
Total: 20 µL 
The reaction was mixed thoroughly with constant shaking and then incubated at 37 °C for 
30 min. The reaction products were purified with Qiagen PCR purification kit (28104, 
Qiagen). The manufacturer’s protocol was followed for PCR purification. 
Bacterial transformation 
SoloPack® Gold supercompetent cells (230350, Agilent Technologies) were used 
for bacterial transformation. One microliter of ligation reaction product was added to10 
µL of the competent cells for each transformation reaction. After a 30 min incubation on 
ice, the competent cells were heat-shocked at 42 °C for 30 s and then incubated on ice for 
an additional 2 min. A 30 min recovery at 37 °C with a 300 µL pre-warmed SOC 
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medium (340-031-671, Quality Biological) was performed before the cells were spread 
onto an LB/agar plate with antibiotics for colony selection.  
Colony screening was performed with Taq polymerase PCR reaction, as described 
above, to check the correct insertion of DNA sequences into the vector. Miniprep kit 
(A1222, Promega) and maxiprep kit (11-555(D4202), Genesee Scientific (Zymo 
research)) were used for plasmid extraction. The manufacturer’s protocol was followed 
for the miniprep and maxiprep reactions. The plasmids were then sent for sequencing 
(Genewiz). Glycerol (G5516, Sigma-Aldrich) stock (400 µL glycerol + 600 µL bacterial 
culture) was made and stored in an −80 °C freezer for each bacterial strain carrying the 
correct plasmids. 
 
Site-directed mutagenesis (SDM) 
Partially overlapping primers were designed to improve the efficiency of PCR 
reaction. A PCR reaction (with SDM primers) using Q5 polymerase was carried out, as 
described above. The PCR products were digested with 1 µL DPNI (R0176L, NEB) at 
37 °C for 1 h to remove template DNA. The digestion product was then transformed into 




A mammalian cell culture was prepared, as described above. Two hundred and 
fifty microliters 1 mg/mL sodium arsenite (35000, Fluka) was added to a 2250 µL cell 
medium to reach a final concentration of 100 µg/mL. The cells were then incubated at 
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37 °C and 5% CO2 content for 30 min. A wash with cold PBS was performed to remove 
sodium arsenite before cell harvesting.  
 
Hydrogen peroxide treatment  
 A mammalian cell culture was prepared, as described above; 0.4 µL 30% (w/w) 
hydrogen peroxide (311448, Sigma) was diluted with a 250 µL medium. The mixture was 
then added to a 2 mL cell medium in each well to reach a final concentration of 1 µM per 
well. The cells were then incubated at 37 °C and 5% CO2 content for 10 min. A wash 
with cold PBS was performed to remove hydrogen peroxide before cell harvesting.  
 
PFA fixation 
 Sterilized cover glasses were placed in each well of the six-well plate before cell 
seeding. A wash with PBS was performed to remove residual ethanol from the 
sterilization process. HeLa cells were seeded, incubated, and transfected, as described 
previously. After a 24 h incubation, the cover glasses were transferred to a 24-well plate 
and washed with PBS. Then, 4% PFA (15714, Electron Microscopy Science) in PBS was 
added in each well for cell fixation. After a 10 min incubation, the cover glasses were 
washed with PBS to remove PFA. The cover glasses were then incubated with 1% Triton 
X-100 (T8787, Sigma) in PBS at room temperature for 10 min to permeabilize the cell 
membrane, followed by an additional wash with PBS. The cells were then blocked with 
1% donkey serum in PBST (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4) at room temperature for 30 min. Primary antibody (1:100 in PBST with 1% 
donkey serum) was added on top of each cover glass and incubated at room temperature 
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for 1 h. The cover glasses were then washed with PBST three times before they were 
incubated with the diluted secondary antibody (1:500 in PBST with 1% donkey serum) 
for 30 min, followed by an additional wash with PBST. The cover glasses were stained 
with 1 µM DAPI for 5 min and rinsed with PBS before they were fixed on slides with 
ProLong Gold® Antifade Mountant (P36934, Life Technologies). A layer of nail polisher 
was applied around the cover glasses to seal the gap. The slides were visualized with a 
DeltaVision Elite deconvolution microscope (29065728, GE healthcare Life Science). 
The following antibodies were used for immunofluorescence microscopy: rabbit 
polyclonal anti-PAR antibody (4336-BPC, Trevigen, USA), mouse anti-GFP 
(11814460001, Roche, USA), rabbit anti-TNKS 1&2 (H-350) (sc-8337, Santa Cruz, 
USA), anti-axin (AF3287, R&D System, USA), and goat anti-eIF3η (sc-16377, Santa 
Cruz Biotechnology, USA).  
  
Methanol fixation 
 The steps were the same as described in the PFA fixation, except for the use of 
methanol for cell fixing and permeabilization instead of 4% PFA and 1% Triton X-100. 
One milliliter of cold methanol (100208, Thermo Fisher) was added to each well and 












Table I. List of PCR Primers 
Primer Sequence Note 
HW001_RNF146_sgRNA-
1_plus 
CAC CGT CTT TAA CCG TCC 





AAA CCA TTC AGG GAC GGT 





CAC CGA CAA ACA GGA AAG 





AAA CTC GTT CGC TTT CCT 




























CAC CGA CAG CTC CAG CCC 




AAA CCT GGG GCG GGC TGG 

















CAC CGC TGT TCG AGG CGT 





AAA CTT GCG GCA CGC CTC 
















CAC CGA TGT CGG GTC GCC 




AAA CGC GCA GCG GCG ACC 
CGA CAT C 
sgRNA-minus-PARP5b-Benchling-
01 
HW019_pSpCas9_F (4-23) GGCCTATTTCCCATGATTCC Universal DNA primers for 
amplification of target insertion 
region (327 bp) on pSpCas9 (BB)-





Universal DNA primers for 
amplification of target insertion 
region (327 bp) on pSpCas9 (BB)-
2A-GFP (px458) plasmid 
HW021_SURVEYOR_RN
F146_F 
CCT TTT CCC CTC ACT GGA 
TGC 
Primers for SURYEYOR assay 
HW022_SURVEYOR_RN
F146_R 
GCT TGT CAA GGA AAT CCT 
CGG G 
Primers for SURYEYOR assay 
HW023_SURVEYOR_TN
KS1_F 
CCG TTC CCT TGG CTG TTC 
TCT 
Primers for SURYEYOR assay 
HW024_SURVEYOR_TN
KS1_R 
CGG GGA AGA AGA GGA CGA 
CG 
Primers for SURYEYOR assay 
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Primer Sequence Note 
HW025_SURVEYOR_TN
KS2_F 
GAT CCG GTG ACA GCA GGG 
AG 
Primers for SURYEYOR assay 
HW026_SURVEYOR_TN
KS2_R 
GTC CCC ACT GGA AGA GAG 
CG 
Primers for SURYEYOR assay 
HW027_hRNF146_Forwar
d 
GTC TCG AGC TAT GGC TGG 
CTG TGG TGA AAT TG 
Primer for cloning human RNF146 
HW028_hRNF146_Revers
e 
GTG GAT CCT TAA ACT TCA 
GTT ACT GTG 
Primer for cloning human RNF147 
HW029_hRNF146_Q153A
_Forward 
TCG CTG ATC TTG AAA ACA 
TGG TTG CAT ATA GGA GAA 
ATG AAC ATG GAC 
Primer for SDM human RNF146 
HW030_hRNF146_Q153A
_Reverse 
GTC CAT GTT CAT TTC TCC 
TAT ATG CAA CCA TGT TTT 
CAA GAT CAG CGA 
Primer for SDM human RNF147 
HW031_5GEX_hRNF146_
C-tar 
GGG CTG GCA AGC CAC GTT 
TGG TG 
Sequencing primer  
HW032_3GEX_hRNF146_
C-tar 
CCG GGA GCT GCA TGT GTC 
AGA GG 
Sequencing primer  
HW033_T7tem_hRNF146_
FL 
GCT AGT TAT TGC TCA GCG G Sequencing primer  
HW034_T7prom_hRNF14
6_FL 
TAA TAC GAC TCA CTA TAG 
GGG AAT TG 
Sequencing primer  
HW033_hRNF146_RING_
WWE_Forward 
GTC TCG AGC TCC TTC TTT 
AAC CGT CCC TGA ATG TG 




GTG GAT CCT TAT AGC CTA 
AGT CCA GCT ACT CCC TTC 




GTC TCG AGC TAA TGG TGA 
ATA TGC ATG GTA TTA TGA 
AGG AAG 




GTG GAT CCT TAA ACT TCA 
GTT ACT GTG CAC TGT CCA 
TC 




GCG TCT CGA GTA ATT TAC 
CAC ACA GTC TGG AAA TTC 
TTC 




GCT GGA TCC TTA CTG TAA 
ATA TGG AAG CAG TAT AAA 
ACA GG 




GCG TCT CGA GTA GAT ACC 
CAG TGG GGC TGG 




GCT GGA TCC TTA CTC GTT 
TTC ACA GAT GTA ACT GAA 
AGC 




GCG TCT CGA GTA ACC ACC 
AAA TGG ATT TGG TAT TGG 




GCT GGA TCC TTA TCT CTT 
CAT CTG CTG CAC ATA CC 




GCG TCT CGA GTA GAA CAG 
GAA TCC CGG GC 




GCT GGA TCC TTA CAT ATC 
ACT CCA GTG TGC AGG 




GCG TCT CGA GTA CAT TTG 
CCG TAT CGA TGG CAA 
Primer for cloning human PARP 12 
WWE (1st) 
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Primer Sequence Note 
HW048_PARP12 WWE1 
cloning Rev 
GCA TGA ATT CTT AGA GGA 
TGA AGT GTG GAG GTT TG 




GCG TCT CGA GTA ACC ACT 
GAC TGG ATT TGG TAC TG 




GCA TGA ATT CTT AGG TTT 
GCA TGG TCG TCA CAT C 




GCT GGA TCC TAA TGG TGA 
ATA TGC ATG GTA TTA TGA 
AGG AAG 




GCA ACC GGT GCT AGC CTA 
AGT CCA GCT ACT CCC TTC 
Primer for cloning Mitochondria-
WWE(hRNF146) 
HW053_FPN1.rev GTC GCC GTC CAG CTC GAC 
CAG 
Sequencing primer  
HW055_SDM_hRING_K6
1A_Forward 
GCA CGT TTT CTG CTA TCT 
ATG TGT AGC AGG AGC TTC 
ATG GCT 




AGC CAT GAA GCT CCT GCT 
ACA CAT AGA TAG CAG AAA 
ACG TGC 




CAT AGA TAG CAG AAA ACG 
TGC TTA CAG GGC AGA CTG 
ACT G 
Primer for SDM RING Domain 
(human RNF146) 
HW059_hULF-WWE for. CGT ACG AAT TCA GGA AAT 
GCA CAG AAC ACA GAT GG 
Primer for cloning human ULF 
WWE 
HW060_ hULF-WWE rev. GTG GAT CCC TAA AGC TGT 
GCT CGA GCA TC 
Primer for cloning human ULF 
WWE 
HW061_R163A SDM for. GTC GCG CGA AGA TTA AGC 
GAG ATA TAA TAG ATA TAC 
CAA AGA AGG G 
Primer for SDM WWE Domain 
(human RNF146) 
HW062_R163A SDM rev. CTT AAT CTT CGC GCG ACG 
TCC ATG TTC ATT TCT CCT 
ATA TTG AAC 
Primer for SDM WWE Domain 
(human RNF146) 
HW063_Y144A SDM for. CTT TCT GGC TGT CGC TGA 
TCT TGA AAA CAT GGT TCA 
ATA TAG GAG 
Primer for SDM WWE Domain 
(human RNF146) 
HW064_Y144A SDM rev. CAG CGA CAG CCA GAA AGC 
CAG CAA TTA ACA TTT CAG 
TGT TC 




GTC TCG AGC TTC CTT CGA 
ACT CAT AGA CAT GGA C 




GTG GAT CCT TAA GAC CCT 
GCA ATT GGC TG 




GTC TCG AGC TAA CGT GGC 
CAG GGT GG 




GTG GAT CCT TAT TGC GAC 
TTG GGA ATG GAG C 
Primer for cloning mouse Deltex1 
WWE 
HW069_New 1st WWE 
For. 
GCA TCT CGA GCT AAT GGT 
GAG TAC GCT TGG TAC TAC 
Primer for PCR amplification of 
synthesized oligos of 1st WWE 
domain (XhoI-WWE-HindIII)  
HW069_New 1st WWE 
Rev. 
GCT CAA GCT TGA GTC TCA 
GAC CCG CAA CAC C 
Primer for PCR amplification of 
synthesized oligos of 1st WWE 
domain (XhoI-WWE-HindIII)  
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pEGPFP-PARP12 WWE (1st) 
pEGPFP-PARP12 WWE (2nd) 
pEGPFP-PARP12 WWE-WWE 
pEGPFP-mito-WWE 
pEGFP-mDeltex 1WWE  
pEGFP-hULF WWE  
pEGFP-hRNF146 WWE Y144A  







pSpCas9 (anti-RNF146 sgRNA1) HW 001/002 
pSpCas9 (anti-RNF146 sgRNA2) HW 003/004 
pSpCas9 (anti-RNF146 sgRNA3) HW 005/006 
pSpCas9 (anti-TNKS1 sgRNA1) HW 007/008 
pSpCas9 (anti-TNKS1 sgRNA2) HW 009/010 
pSpCas9 (anti-TNKS1 sgRNA3) HW 011/012 
pSpCas9 (anti-TNKS2 sgRNA1) HW 013/014 
pSpCas9 (anti-TNKS2 sgRNA2) HW 015/016 







Overexpression of human RNF146 mimics the PAR-induction effect by mouse RNF146 to 
a lesser extent 
Amino acid sequence alignments showed that mouse and human RNF146 
(mRNF146 and hRNF146) share 92% overall homology (Figure 5a). Moreover, the 
RING and WWE domains are 100% identical. We therefore investigated whether 
expression of hRNF146 could lead to a similar induction of endogenous PAR levels 
observed in cells expressing mRNF146. The cDNA of hRNF146 was cloned into the GFP 
expression vector pEGFP-c1 and expressed in 293T cells through transfection, where the 
GFP-tagged mRNF146 construct was transfected as a positive control. The level of 
endogenous PAR induction by overexpressing hRNF146 was 6-7 folds lower than that 
caused by mRNF146 or its WWE domain (Figure 5b). The difference is therefore likely 
due to the region outside the conserved RING and WWE domains.  
The nature of induction in PAR levels by RNF146 is not known. One hypothesis 
is that such induction could be partially due to elevated levels of PARylated cellular 
proteins. On the other hand, however, overexpression of ubiquitin E3 ligase RNF146 
should result in a decrease in levels of PARylated proteins, in particularly PARdU 
substrates, thus reducing overall cellular PARylation level. In order to test the conflicting 
ideas, we chose to examine endogenous Tankyrase 1 & 2 (TNKS1/PARP5a and 
TNKS2/PARP5b) because they are continually auto-PARylated in cells (Callow et al., 
2011) as well as the fact that they are known PARdU substrates of RNF146. To our 
surprise, analysis by western blot revealed that cells overexpressing mRNF146 or its 
WWE domain, compared to those expressing hRNF146, had elevated levels of TNKS 1 
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& 2 (Figure 5c). In addition, the levels of increase in the amount of PARylated TNKS 
proteins were comparable in cells expressing full-length mRNF146 or its WWE domain. 
It seems that overexpression of mRNF146 resulted in a stabilization of PARylated TNKS 
proteins, similar to overexpression of mRNF146 WWE domain, rather than enhancing 
protein degradation. It was also possible, however, the increased signals of TNKS 1 & 2 
detected on western blots could be purely due to a stabilization of attached PAR chains 
on PARylated proteins rather than a change in amounts of proteins. As a result, in the 
following content of this thesis, the term “increased levels of PARylted TNKS 1 & 2” is 
used referring to elevated TNKS signals detected on western blots caused by either of the 
two mechanisms until further experiments could distinguish them apart in the near future.  
 
(Next page) Figure 5 | Overexpression of hRNF146 leads to lower levels of PAR-
induction compared to mRNF146. a) Protein sequence alignment between hRNF146 
(labeled in green) and mRNF146 (labeled in red). Regions for RING and WWE domains 
are highlighted. b) Western blot of cell lysates from 293T cells expressing GFP-tagged 
hRNF146, mRNF146 and mRFN146 WWE domain using antibodies against PAR (left) 
and GFP (right). c) Western blot of the same cell lysates using antibodies against TNKS 1 








Overexpression of RNF146 WWE domain alone is sufficient to increase endogenous PAR 
levels 
Our analyses found that overexpression of the mRNF146 WWE domain alone 
was sufficient to increase the endogenous PAR levels although the pattern of PAR 
induction was slightly different from that caused by overexpressing full-length 
mRNF146. Nonetheless, the expression of full-length hRNF146 had a more limited effect 
on PARylation despite 100% conservation of the WWE domain. We hypothesize that the 
regions outside of the hRNF146 WWE domain negatively regulates the induction on 
PAR levels when full-length hRNF146 is expressed in cells. To further analyze the 
regions of hRNF146 responsible for affecting PAR levels, various protein fragments of 
hRNF146 were cloned into pEGFP-c1 vectors (Figure 6). GFP-tagged recombinant 
proteins were overexpressed in 293T cells for 24 h after transfection. Cell lysates were 
collected and analyzed on western blot. As we expected, overexpression of the GFP-
tagged human RNF146 WWE domain alone was able to increase cellular PARylation 
levels (Figure 7a). In contrast, addition of other regions (RING–WWE or WWE–Cter) 
did not increase PAR levels. 
To determine whether the differences in effects on PARylation could be due to 
different expression levels of RNF146 protein fragments, a dose-dependent transfection 
assay was performed. Expressing the hRNF146 WWE domain increased endogenous 
PAR levels as the expression levels increased, whereas expressing varying levels of full-




Figure 6 | Diagram for full-length hRNF146 and its truncated protein fragment 
constructs. The RING domain (30-85) is highlighted in purple and WWE domain (101-
183) is highlighted in pink. The C-terminus region is highlighted in yellow with roman 
numerals indicating potential TNKS interacting sites. 
 
(Next pages) Figure 7 | Overexpression of hRNF146 WWE domain is sufficient to 
increase cellular levels of PAR as well as TNKS 1 and 2. a) Western blot of cell lysates 
from 293T cells over-expressing GFP, GFP-tagged full-length hRNF146 and hRNF146 
protein fragments (RING–WWE, WWE, WWE-Cter) using antibodies against PAR (left) 
and GFP (right). According to manufacturer’s protocol, the PAR antibody cross-reacts 
with bovine serum albumin (left, 66 kDa) from the cell medium. (The same situation 
applies to all following western blots against PAR staining) b) Western blot of the same 






Figure 8 | Overexpression of wild-type hRNF146 WWE domain but not full-length 
hRNF146 increases endogenous PAR level in a dose-dependent manner. Western blot 
of cell lysates from 293T cells over expressing GFP-tagged RNF146 and its WWE 
domain using antibody against PAR (top) and GFP (bottom). pUC18 plasmid was 




Again, we examined the endogenous levels of TNKS 1 & 2. Compared to cells 
expressing hRNF146, hRNF146 RING-WWE and GFP, overexpression of the hRNF146 
WWE domain as well as the WWE–Cter construct increased levels of PARylated TNKS 
1 & 2 in cells (Figure 7b). Notably, overexpression of WWE–Cter increased the total 
PARylated TNKS 1 & 2 levels without necessarily inducing the endogenous PAR level. 
One potential explanation is that the Cter region is known to contain five Tankyrase 
binding motifs (DaRosa et al., 2015); thus, overexpression of WWE–Cter might 
potentially stabilize the interaction, resulting in an increase in TNKS 1 & 2 levels.  
As mentioned above, PARylated TNKS 1 & 2 were targets of RNF146 (as well as 
the RNF146 RING–WWE fragment) ubiquitin E3 ligase activity (Callow et al., 2011). 
We reasoned that overexpressing hRNF146 with impaired E3 activity in cells could 
further result in elevated levels of PARylated TNKS 1 & 2 compared to expressing wild-
type hRNF146 in cells. As a result, site-directed mutagenesis was conducted to change 
the Lys61 residue to Ala (See also Introduction). Mutations at the Lys61 residue in the 
RNF146 RING domain uncouples its ubiquitin E3 ligase activity from the PAR-binding 
ability of WWE domain; the mutant exhibits constitutive basal E3 ligase activity  as 
binding of PAR polymers cannot activate the RING domain (DaRosa et al., 2015; See 
also Introduction). As expected, overexpression of human RNF146 K61A mutant showed 
a higher induction in PARylated TNKS 1 & 2 levels than the levels induced by wild-type 
RNF146 (Figure 9). Moreover, basal E3 activity potentially explains the difference in 
TNKS levels induced by overexpressing the WWE domain and by overexpressing 
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RNF146 K61A mutant. Whether the increase in PARylated TNKS1 and 2 is part of an 
increase in endogenous PAR levels will be followed up in the future. 
 
 
Figure 9 | Mutations in the RING domain lowers the level of TNKS 1 & 2 induction 
caused by overexpressing hRNF146. Western blot of cell lysates from 293T cells 
overexpressing GFP-tagged RNF146, its protein fragments (RING–WWE, WWE, 
WWE–Cter) and the mutant (K61A) in 293T cells. K61A RNF146 #1 and #2 were 









PAR induction by hRNF146 WWE is dependent on high affinity binding to iso-ADPr 
Given that the primary function of the RNF146 WWE domain is to bind to iso-
ADPr, we tested if its affinity toward PAR correlates with levels of PAR induction 
detected on western blots. A mutation changing Gln153 to Ala in the hRNF146 WWE 
domain impairs its affinity to iso-ADPr (Figure 2b).	The GFP-tagged hRNF146 Q153A 
WWE domain was overexpressed in 293T cells along with the wild-type WWE domain 
as the positive control (Figure 10). PAR levels increased in a dose-dependent manner 
with increasing expression of the wild-type WWE domain but not with the Q153A 
mutant. In fact, endogenous PAR levels in cells expressing the Q153A mutant were 
equivalent to those in negative control cells (transfected with the pUC18 plasmid) –an 
induction in PARylated TNKS levels was once again detected by overexpressing wild-
type WWE but not the Q153A mutant. To investigate whether the hRNF146 WWE has a 
general effect on increasing PARylation of all PARylated proteins we also probed for 
PARP1—a well-established target that is PARylated upon DNA damage. Both the 
protein levels and PARylation levels of PARP1 remained the same across the samples 
(Figure 11), suggesting that overexpression of the RNF146 WWE domain only increases 




Figure 10 | Mutation reducing PAR binding affinity impairs cellular PAR induction 
by hRNF146 WWE domain. Western blot of cell lysates from 293T cells over 
expressing GFP-tagged wild-type hRNF146 WWE domain and PAR-binding deficient 






Figure 11 | Mutations that reduce PAR binding affinity impair TNKS 1 & 2 but not 
PARP1 induction levels by hRNF146 WWE domain. Western blot of cell lysates from 
293T cells over expressing GFP-tagged wild-type hRNF146 WWE domain and PAR-
binding deficient mutant Q153A WWE domain using antibody against PAR (left), TNKS 
1 and 2, GFP, β-actin and PARP1 (right, from top to bottom).  
 
To further examine the correlation between PAR-binding affinity and PAR-
induction ability of RNF146 WWE domain, additional PAR-binding-deficient WWE 
mutants were generated by site-directed mutagenesis. Previous ITC data suggested that 
Y144A and R163A mutants showed no detectable interactions with iso-ADPr in vitro 
(Figure 2b). Expressing these WWE mutants in 293T cells led to negligible PAR 
inductions even though the same relative amounts of each expressed protein were 
detected compared to the wild-type WWE domain (Figure 12a). Consistently, no TNKS 1 
& 2 induction was identified among cells expressing these mutants (Figure 12b).  
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Figure 12 | Mutations that reduce PAR affinity of RNF146 WWE domain impairs 
level of PAR/TNKS 1 & 2 upon overexpression. Western blot of cell lysates from 293T 
cells overexpressing GFP-tagged wild-type (w.t.) RNF146 WWE domain and its PAR-
binding deficient mutants in 293T cells using antibodies against PAR (a, top), GFP (a, 







PAR induction by overexpressing the RNF146 WWE domain in multiple cell lines. 
 As the data presented above were generated with the 293F or 293T cell lines, we 
tested a similar dose-dependent transfection procedure in both HeLa and DLD1 cells to 
determine if the results could be reproduced in other cell lines. While an increase in 
cellular PAR levels was indeed observed after overexpressing the wild-type RNF146 
WWE domain in both cell lines, PAR signals detected on western blot from DLD1 cell 
lysates were much weaker than PAR signals from 293F/T and HeLa (Figures 13 and 14). 
Low transfection efficiency in DLD1 cells (less than 20% of the total cells, data not 
shown) could be a possible explanation for the weaker induction of PAR signals. 
 
(Next page) Figure 13 | Overexpressing hRNF146 WWE domain induces cellular 
PAR in HeLa cells. Western blot of cell lysates from HeLa cells over expressing GFP-
tagged wild-type hRNF146 WWE domain and PAR-binding deficient mutant Q153A 






Figure 14 | Overexpressing hRNF146 WWE domain induces cellular PAR in DLD1 
cells. Western blot of cell lysates from DLD1 cells over expressing GFP-tagged wild-
type hRNF146 WWE domain and PAR-binding deficient mutant Q153A WWE domain 






Overexpression of the wild-type RNF146 WWE domain but not the mutant leads to 
puncta formation in cells  
 Limited transfection efficiency as well as low protein expression in both HeLa 
and DLD1 cells led us to explore if results could be observed on a single-cell scale so that 
any significant effect would not be underestimated by untransfected cells. HeLa cells 
were chosen for further examination because of its moderate expression of GFP-tagged 
recombinant proteins. After transfections, cells were fixed on slides for immunostaining 
and visualized by fluorescence microscopy. Overexpression of the GFP-tagged wild-type 
RNF146 WWE domain led to a formation of individual puncta in the cytoplasm of HeLa 
cells (Figure 15, GFP channel). Co-staining with anti-PAR antibodies revealed co-
localization between endogenous PAR and the GFP-tagged RNF146 WWE domain 
(Figure 15, Merged channel), compared to diffuse pattern of PAR observed in 
untransfected cells. Additionally, expressing GFP (data not shown) or the GFP-tagged 
RNF146 WWE Q153A mutant failed to produce any visible puncta (Figure 15). Thus, 
puncta formation correlated with the PAR-binding affinity of the RNF146 WWE domain. 
However, puncta were not detected in all cells expressing the GFP-tagged RNF146 
WWE domain, suggesting that other factors, such as cell cycle stage, could contribute to 





Figure 15 | Wild-type RNF146 WWE domain induces formation of PAR-rich puncta 
in cells. Untransfected HeLa cells (first row) were treated with 1 µM hydrogen peroxide 
for 10 minutes to induce detectable PAR staining (second row). Immunofluorescence 
microscopy images of HeLa cells expressing either GFP-tagged wild-type RNF146 
WWE domain (third row) or PAR-binding deficient mutant Q153A WWE domain 
(bottom row) using antibodies against PAR.  
 
 Martino-Echarri et al. (2016A) previously reported the formation of axin-rich 
puncta after TNKS 1/2 inhibition. Their model suggested that PARP inhibitor treatments 
caused aggregation of the Axin1-TNKS 1 & 2 complex, which led to formation of visible 
puncta in cells. Thus, we looked for a similar mechanism in the formation of puncta in 
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cells overexpressing the RNF146 WWE domain. We found that GFP-tagged wild-type 
RNF146 WWE co-localized with TNKS 1 & 2 (Figure 16a). We have yet to verify 
whether or not Axin1 co-localizes with these loci. In addition, we also investigated 
whether the puncta were part of stress granules by immunostaining with antibodies to 
eIF3 (Kedersha et al., 2001). Co-localization with eIF3 was not detected, indicating that 
the puncta were not part of stress granules (Figure 16b, c). 
 
(Next page) Figure 16 | Wild-type RNF146 WWE domain co-localizes with TNKS 1 
& 2, but not the stress granule marker eIF3. Immunofluorescence microscopy images 
of HeLa cells expressing either GFP-tagged wild-type RNF146 WWE domain or PAR-
binding deficient mutant Q153A WWE domain using antibodies against TNKS 1 & 2 (a) 
and eIF3 (b). Untransfected HeLa cells were treated with 250 µM sodium arsenite for 30 









                 
	 49	
Discussion 
In this thesis, we report a novel phenomenon of RNF146 and its WWE domain. 
Overexpression of RNF146 and the WWE domain in cells increases endogenous PAR 
levels detected by western blots and immunofluorescence microscopy. We also showed 
that this increase in cellular PAR levels was partially due to the elevated levels of certain 
PARylated proteins, such as TNKS 1 & 2. Moreover, the level of PAR induction was 
tightly linked with the PAR-binding affinity of the RNF146 WWE domain. Although 
both mouse and human RNF146 WWE domains were capable of increasing endogenous 
PAR levels to a similar extent, overexpression of two full-length RNF146 proteins 
showed different PAR profiles detected on western blot. At the same time, the distinct 
levels of PARylated TNKS 1 & 2 induction by mouse and human RNF146 were also 
observed. The major differences in primary protein sequences of mouse and human 
RNF146 lie in the N-terminus as well as the C-terminal region downstream of their 
WWE domains. As mentioned above, potential TNKS-interacting motifs lie at the C-
terminus of the RNF146 protein. Whether interaction between the RNF146 C-terminus 
and TNKS 5ARC domain is a requirement for TNKS degradation through ubiquitination 
and whether the differences in C-terminus between mouse and human RNF146 affect the 
levels of PAR/TNKS induction are questions worth exploring in the near future. 
Consistent results of PAR induction by RNF146 WWE domain overexpression 
have driven our curiosity toward the molecular mechanism behind this phenomenon. 
Although we cannot exclude the possibility that overexpressing the RNF146 WWE 
domain could directly or indirectly boost formation of new PAR polymers, we favor the 
idea that interaction between the WWE domain and PARylated proteins prevents removal 
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of PAR chains by hydrolases and blocks protein degradation by endogenous enzymes, 
such as PAR-dependent ubiquitin E3 ligases. As a result, a prolonged life span of 
PARylated proteins has been translated into elevated PAR levels revealed on western 
blot.  
  We also illustrated the formation of TNKS-rich puncta in the cytosol by 
overexpressing the RNF146 WWE domain. Moreover, our data also indicated the 
possible presence of PARylated TNKS proteins within the puncta induced by 
overexpressing the RNF146 WWE domain, as demonstrated by the following evidence: 
First, expressing a PAR-binding deficient mutant, the RNF146 Q153A WWE domain, 
failed to generate visible puncta in cells. Second, expressing the wild-type WWE domain 
in the mitochondria also inhibits puncta formation, which is likely due to the spatial 
separation between the WWE domain and TNKS proteins (See below, Figure 19).  
In addition, another study revealed that overexpressing the TNKS proteins or 
inhibiting TNKS activities facilitated assembly of TNKS-rich puncta in cells. Meanwhile, 
removing or mutating the sterile alpha motif (SAM) domain, a domain that facilitates 
self-oligomerization of TNKS proteins, inhibits visible puncta formation caused by 
overexpression (De Rycker and Price, 2004). In addition, auto-PARylations of TNKS 
proteins have been shown to increase protein solubility by preventing self-
oligomerization in vitro (DaRosa et al., 2016). All the evidence suggests that PARylation 
inhibits TNKS oligomerization and leads to a change in protein solubility. How 
overexpression of RNF146 WWE promotes formation of TNKS-containing pucta while 
potentially stabilizing its PARylation is the question we would like to pursue in the near 
future. 
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RNF146 WWE domain as a potential tool for modulating endogenous PARylation levels 
in different subcellular compartments 
 As mentioned in the Introduction, due to different localizations of PARPs, 
PARylation events in each subcellular compartment could lead to a distinct physiological 
significance for normal cellular activities. Thus, modulating subcellular PARylation 
could be useful for further identifying different aspects of PARylation in cells. Induction 
in endogenous PAR levels by overexpressing the RNF146 WWE domain has led us to 
explore the possibility of artificially altering endogenous PARylation in different cellular 
compartments.  
First, we investigated the relative strength of PAR induction by the RNF146 
WWE domain. A simple comparison was performed between the level of PAR increase 
by PARG inhibition and by RNF146 WWE overexpression. Transfected cells were 
treated with or without a membrane-permeable PARG inhibitor (a gift from Dr. Ian 
Waddell, Cancer Research UK, Manchester) for 2 h before harvesting. Compared with 
cells expressing the wild-type RNF146 WWE domain (without PARG inhibitor 
treatment), untransfected cells treated with the PARG inhibitor showed a similar level but 
distinct pattern of PAR signals (Figure 17). PARG treatment with WWE-expressing cells 
led to an even higher level of PAR increase. PARG inhibition is known to cause a global 
increase in cellular PAR; but effective as it is, PARG inhibition is detrimental to cells 
(Stowell et al., 2016). In contrast, the RNF146 WWE domain may provide a way to fine-







Figure 17 | Overexpression of hRNF146 WWE domain mimics cellular PAR 
induction by PARG inhibition. a) Western blot of cell lysates from 293T cells 
overexpressing GFP-tagged RNF146 WWE domains and PAR-binding deficient mutant 
Q153A WWE domain with/without PARG inhibitor treatment, using antibody against 
PAR (top), GFP (middle) and β-actin (bottom). b) Western blot of the same cell lysates 




Next, we checked if RNF146 is the best candidate for PAR induction among the 
WWE domain family. DNA sequences of different WWE domains were cloned into 
pEGFP-c1 and expressed in 293T cells. Expressing the RNF146 WWE domain led to the 
strongest PAR induction, as previously observed. Several PARP WWE domains showed 
weak or no PAR increase in general (Figure 18). To date, overexpressing the RNF146 
WWE domain demonstrated the strongest PAR induction. PARP 7 WWE domain and 
other E3 ligase WWE domains will be tested in the future. 
 
(Next page) Figure 18 | Overexpressing WWE domains from various PARPs showed 
negligible PAR induction compared to RNF146 WWE domain. Western blot of cell 
lysates from 293 T cells over-expressing GFP-tagged WWE domains in 293T cells using 
antibodies against PAR (left) and GFP (right). The “PAPR12 WWE 1” and “PARP12 
WWE 2” refer to GFP-tagged recombinant proteins containing either PAPR12 WWE 
domain. The “PAPR12 WWE (both)” refer to GFP-tagged recombinant protein 











 By attaching different localization signals, we transported the GFP-tagged 
RNF146WWE domain into subcellular compartments and visualized them by 
fluorescence microscopy. A mitochondrial-matrix-targeting peptide sequence subunit 9 
(Su9) of the F0-ATPase, was attached to the N-terminus of the WWE domain while the 
GFP sequence was fused to the C-terminus (Haucke et al., 1995). Expressing the Su9-
WWE-GFP recombinant protein in HeLa cells resulted in a distinct pattern of distribution 
in the cytoplasm (Figure 19). Immunostaining against PDH, a mitochondrial marker, 
further confirmed the correct localization of the Su9-WWE-GFP protein to mitochondria 
(data not shown). However, we were not able to detect any visible puncta formed by the 
Su9-WWE-GFP protein; neither did we see any co-localization between PAR and GFP 
signals as seen for the untargeted WWE construct. Our data are consistent with the 
absence of any PARPs identified in mitochondria.  
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Figure 19 | Targeting RNF146 WWE domain into Mitochondrial matrix inhibits 
formation of PAR-rich puncta in the cytoplasm. Immunofluorescence microscopy 
images of HeLa cells expressing GFP-tagged RNF146 WWE domain in mitochondrial 
matrix using antibody against PAR. 
 
Along with exploring the potential for developing the RNF146 WWE domain as a 
general tool for modulating cellular PAR levels, several questions remain unanswered. 
First, it is still unclear whether the RNF146 WWE domain shows any binding specificity 
bias toward PARylated proteins. The crystal structure of RNF146 WWE domain-binding 
iso-ADPr provided the theoretical basis for its potential interaction with the majority of 
PARylated proteins in cells. In addition, the recombinant RNF146 WWE domain is 
available commercially as a reagent for detecting cellular PARylation. However, no 
systematic study has been done to demonstrate the substrate specificity of the RNF146 
WWE domain. In addition, our data suggested that neither protein level nor PARylation 
levels of endogenous PARP1 was affected by overexpression of hRNF146 WWE 
domain. Second, the strength of PAR induction by the RNF146 WWE domain remains to 
be further tested. The level of PAR induction is comparable between PARG inhibition 
and WWE overexpression, yet the specific bands of PARylated proteins seem to be 
differed. Thus, these data indicated that either the RNF146 WWE domain was able to 
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increase the concentration for a particular subgroup of PARylated proteins or the 
preservation of cellular PAR levels was relatively inefficient compared to PARG 
inhibition. A systematic identification and analysis of individual PARylated proteins is 
needed in order to gain further insights into substrate specificity of RNF146 WWE 
domain. Stable isotope-labeled with amino acids in cell culture (SILAC), a method for 
quantitative proteomic analysis (Ong et al., 2002), would allow us to quantitatively 
identify which PARylated proteins are increased upon overexpression of RNF146 WWE 
domain. Meanwhile, additional mass-spectrometry analysis, using the RNF146 WWE 
domain as a bait to pull down endogenous PARylated proteins, can be utilized to further 
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